The FDA approves the Embrace Hydrogel Embolic System, offering a groundbreaking treatment for hypervascular tumors in ...

Instylla, Inc. announced premarket approval (PMA) from the FDA for the company’s flagship Embrace hydrogel embolic system.

Instylla, Inc., a privately held company developing novel resorbable embolics for peripheral vascular embolization, announced ...

The global transcatheter embolization and occlusion (TEO) devices market is set for rapid growth, driven by increasing preference for minimally invasive procedures in oncology, neurology, and other ...

Japanese drugmaker Eisai revealed that its in-house discovered tyrosine kinase inhibitor, Lenvima (lenvatinib mesylate), in combination with the anti-PD-1 antibody, pembrolizumab, and transarterial ...

(9926.HK) (“Akeso” or the “Company”) announced that its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225) has been approved to initiate by both China’s National ...

Emma Bainbridge is fundraising so she can travel to Germany for experimental cancer treatment.

Due to the increasing rate of obesity, cases of liver cancer are expected to double by 2050. This claim has been made in a ...

TACE (Transarterial Chemoembolization): Delivers chemo directly to liver tumours while blocking their blood supply. These methods are useful for patients who are not candidates for surgery or systemic ...

Transcatheter arterial chemoembolization (TACE) is thought to prevent recurrence, but its efficacy is a matter of controversy. 4 OBJECTIVES To analyze the effect of preventive TACE on recurrence rates ...